We are pleased to announce that the concentrate Altuviiio™ (also named BIVV001), newly approved by FDA, was added on the WAPPS-Hemo platform.
Estimation of Altuviiio’s pharmacokinetics (PK) parameters leverages the population PK model from Bhagunde et al. built on 260 Hemophilia A patients ranging from 12.5 to 133 kg.
Please note that the model was not evaluated for Bayesian forecasting. Results should be reviewed and used with caution.
Clinicians are now able to select Altuviiio™ in WAPPS to receive individual PK estimates for their patients and to use the clinical calculator for dose regimen design.
